Metabolic dysfunction-associated steatotic liver disease (MASLD) inhibits hepatitis B virus (HBV) activity while simultaneously exacerbating liver fibrosis/cirrhosis (LF/LC) in chronic HBV (CHB)-infected patients. To date, no model is available to investigate ... ...

请注册登录后继续浏览